NEW YORK (360Dx) – Becton Dickinson has completed its $24 billion acquisition of C.R. Bard. Starting with BD’s fiscal second quarter, it will report a new interventional segment structure, which will include most of Bard’s offerings, with the remainder reported under BD's existing medical segments. Earlier in the week, the Ministry of Commerce of the People’s Republic of China approved the acquisition, which was the final regulatory approval needed to complete the deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.